Research shows that stereotactic ablative body radiotherapy (SABR) has equivalent outcomes, or potentially improves outcomes for adults with locally advanced, inoperable, non-metastatic pancreatic carcinoma (LANPC) when compared to longer course chemotherapy and radiation treatment. Treatment with SABR reduces the risk of chemotherapy specific side effects, including the risk of getting infections. Moreover, SABR treatment has shorter duration of treatment, requires less hospital visits and also reduces the frequency of blood test requirements. Collectively, this evidence suggests that access to SABR treatment for LANPC patients can provide the potential for improved tumour control, reduced toxicity and better quality of life.
Radiotherapy is not often used in the treatment of pancreatic cancer, but was utilised more during the pandemic for many of the reasons above. Learning from this, a group of oncologists from the PCC Network were able to quickly collaborate and gain consensus on changing practice and submitted a proposition to NHS England for SABR to be made available as a treatment option for LANPC patients.
We provided support throughout the proposal. First, by ensuring patients and carers had the opportunity to share their perspective on the proposal through facilitating a focus group and survey with members of our Research Involvement Network. Second, by providing supporting feedback on the proposition as part of the NHSE consultation.
As of 2nd November 2021, NHS England recommend that SABR be available as a treatment option through routine commissioning for adults with locally advanced, inoperable, non- metastatic pancreatic carcinoma (LANPC) within the criteria set out in the official document.